Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

References

• HarrisTJDrakeCGPrimer on tumor immunology and cancer immunotherapyJ Immunother Cancer201311224829749
   PubMedGoogle Scholar
• KumarPBhattacharyaPPrabhakarBSA comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunityJ Autoimmun201895779930174217
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJACTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med199117435615691714933
   PubMed Web of Science ®Google Scholar
• QureshiOSZhengYNakamuraKTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4Science2011332602960060321474713
   PubMed Web of Science ®Google Scholar
• RileyJLMaoMKobayashiSModulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptorsProc Natl Acad Sci U S A20029918117901179512195015
   PubMed Web of Science ®Google Scholar
• SchneiderHDowneyJSmithAReversal of the TCR stop signal by CTLA-4Science200631357951972197516931720
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcdermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• BardhanKAnagnostouTBoussiotisVAThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationFront Immunol20167155028018338
   PubMed Web of Science ®Google Scholar
• KeirMELiangSCGuleriaITissue expression of PD-L1 mediates peripheral T cell toleranceJ Exp Med2006203488389516606670
   PubMed Web of Science ®Google Scholar
• FaghfuriEFaramarziMANikfarSAbdollahiMNivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanomaExpert Rev Anticancer Ther201515998199326313415
   PubMed Web of Science ®Google Scholar
• OkazakiTChikumaSIwaiYFagarasanSHonjoTA rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNat Immunol201314121212121824240160
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• KhojaLDayDWei-Wu ChenTSiuLLHansenARTumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnn Oncol201728102377238528945858
   PubMed Web of Science ®Google Scholar
• HasselJCHeinzerlingLAberleJCombined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactionsCancer Treat Rev201757364928550712
   PubMed Web of Science ®Google Scholar
• GirotraMHansenAFarookiATask Force collaborationThe current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for managementJNCI Cancer Spectr201823pky02130057972
   PubMed Web of Science ®Google Scholar
• ZhangSLiangFLiWWangQRisk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysisEur J Cancer201783717928719841
   PubMed Web of Science ®Google Scholar
• HryniewickiATWangCShatskyRACoyneCJManagement of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physiciansJ Emerg Med201855448950230120013
   PubMed Web of Science ®Google Scholar
• GrimaldiAMMarincolaFMAsciertoPASingle versus combination immunotherapy drug treatment in melanomaExpert Opin Biol Ther201616443344126642234
   PubMed Web of Science ®Google Scholar
• ShoushtariANFriedmanCFNavid-AzarbaijaniPMeasuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanomaJAMA Oncol2018419810128817755
   PubMed Web of Science ®Google Scholar
• NagaiHMutoMOptimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and updateInt J Clin Oncol201823341042029516216
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]Common terminology criteria for adverse events (CTCAE) version 5.02018 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed January 23, 2019
   Google Scholar
• HigginsJPAltmanDGGøtzschePCCochrane Bias Methods GroupThe Cochrane collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• AntoniaSJLópez-MartinJABendellJNivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (Check-Mate 032): a multicentre, open-label, phase 1/2 trialLancet Oncol201617788389527269741
   PubMed Web of Science ®Google Scholar
• HellmannMDCiuleanuTEPluzanskiANivolumab plus ipilimumab in lung cancer with a high tumor mutational burdenN Engl J Med2018378222093210429658845
   PubMed Web of Science ®Google Scholar
• WolchokJDChiarion-SileniVGonzalezROverall survival with combined nivolumab and ipilimumab in advanced melanomaN Engl J Med2017377141345135628889792
   PubMed Web of Science ®Google Scholar
• HasselJCHeinzerlingLAberleJCombined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactionsCancer Treat Rev201757364928550712
   PubMed Web of Science ®Google Scholar
• SterneJAGavaghanDEggerMPublication and related bias in meta-analysis: power of statistical tests and prevalence in the literatureJ Clin Epidemiol200053111119112911106885
   PubMed Web of Science ®Google Scholar
• WangDYSalemJECohenJVFatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysisJAMA Oncol20184121721172830242316
   PubMed Web of Science ®Google Scholar
• KomakiYKomakiFYamadaAMicicDIdoASakurabaAMeta-analysis of the risk of immune-related adverse events with Anticytotoxic T-Lymphocyte-Associated antigen 4 and Antiprogrammed death 1 therapiesClin Pharmacol Ther2018103231833128118483
   PubMed Web of Science ®Google Scholar
• Abdel-WahabNShahMSuarez-AlmazorMEAdverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reportsPLoS One2016117e016022127472273
   PubMed Web of Science ®Google Scholar
• ZhangSLiangFZhuJChenQRisk of pneumonitis associated with programmed cell death 1 inhibitors in cancer patients: a meta-analysisMol Cancer Ther20171681588159528446641
   PubMed Web of Science ®Google Scholar
• ZhaoBZhaoHZhaoJSerious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: nivolumab-related serious/fatal adverse eventsJ Immunother Cancer20186110130285872
   PubMed Web of Science ®Google Scholar
• WeberJSDummerRde PrilVLebbéCHodiFSMDX010-20 InvestigatorsPatterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanomaCancer201311991675168223400564
   PubMed Web of Science ®Google Scholar
• VerschurenECvan den EertweghAJWondersJClinical, endoscopic, and histologic characteristics of Ipilimumab-Associated colitisClin Gastroenterol Hepatol201614683684226748223
   PubMed Web of Science ®Google Scholar
• EmensLABraitehFSCassierPAbstract 2859: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)Cancer Res20157515 Supplement2859
   Web of Science ®Google Scholar
• SangroBGomez-MartinCde La MataMA clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJ Hepatol2013591818823466307
   PubMed Web of Science ®Google Scholar